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tiple coreceptor usage has been correlated with disease progression [4, 5, 22, 23] . However, the majority of individuals who do not develop SI variants also progress to AIDS, some of them even rapidly [12, 18] . This was even observed for individuals who were heterozygous for a 32-bp deletion in the CCR5 gene or individuals with a valine to isoleucine substitution in CCR2b [24, 25] , 2 genotypes that, in general, have been associated with a delayed disease progression [24] [25] [26] [27] [28] [29] .
NSI HIV-1 variants isolated from individuals with a progressive disease course replicate more rapidly in vitro and are associated with a higher viral load in vivo than NSI HIV-1 from asymptomatic individuals [18] . In the present study, we analyzed whether these NSI HIV-1 variants associated with a progressive disease course have an expanded coreceptor repertoire and/or whether such a phenomenon may also explain the rapid disease progression in some of the CCR5 D32 heterozygotes and CCR2b-64I carriers who lacked SI HIV-1 variants.
Materials and Methods
Subjects. Sixteen participants of the Amsterdam Cohort Studies on AIDS in homosexual men were analyzed. Eight of these individuals were classified as long-term survivors (LTSs; ACH 16, 68, 78, 337, 434, 441, 583, 750) : they had an asymptomatic followup of at least 9 years (mean follow-up, 144 months after seroconversion; range, 124-152 months) with stable CD4 ϩ T cell counts (1400/mm 3 ) in the absence of antiretroviral therapy [30] . These individuals harbored solely NSI variants. In addition, we studied 4 rapid progressors (AIDS diagnosis at 25-76 months after seroconversion: ACH 53, 172, 424, 638), 3 typical progressors (AIDS diagnosis at 99-109 months after seroconversion: ACH 19, 38, 142) , and 1 slow progressor (AIDS diagnosis at 136 months after seroconversion, after a 10-year period of high and stable CD4 ϩ T cell counts: ACH 617). All progressors also lacked SI HIV-1 variants.
Peripheral blood mononuclear cell (PBMC) samples from at least 2 time points were analyzed. One sample was chosen as early as possible after seroconversion or entry in the cohort studies (mean, 21 and 19 months for LTSs and progressors, respectively). The other sample was chosen as late as possible after seroconversion or entry in the cohort studies (mean, 111 months for LTSs) or at time of AIDS diagnosis (mean, 74 months for progressors; figure  1 ).
CCR5 and CCR2b genotyping. Genomic DNA was isolated from cryopreserved PBMC (Qiagen blood kit, Hilden, Germany). CCR5 genotyping was done by polymerase chain reaction (PCR) analysis by use of primers flanking the 32-bp deletion in CCR5 [24] . CCR2b genotyping was done by restriction fragment length polymorphism PCR analysis as described elsewhere [25] .
Analysis of CD4 ϩ T cell counts. T lymphocyte immunophenotyping for the CD4 ϩ T cells was done at 3-month intervals by flow cytofluorometry. PBMC were stained with CD4 monoclonal antibody according to standard procedures for cell cytometric analysis.
Quantification of RNA in serum. HIV-1 RNA was quantified in serum by use of a nucleic acid sequence based amplification assay (HIV-1 RNA QT; Organon Teknika, Boxtel, The Netherlands) as described elsewhere [31, 32] .
Virus isolation, SI phenotyping, and determination of infectious cellular load. Viruses were isolated under limiting diluting conditions as described elsewhere [12, 20] . Participant PBMC (0.5-cells/well in 32, 48, or 96 wells) were cocultivated with 4 4.0 ϫ 10 phytohemagglutinin (PHA)-stimulated healthy donor peripheral blood lymphocytes (PBL; 10 5 / well) in 96-well microtiter plates. Every week, one-third of the culture supernatants was tested for p24 antigen by an in-house p24 antigen capture ELISA [33] . At the same time, half of the cells was transferred to new 96-well plates, and 10 5 fresh PHA-stimulated healthy donor PBL were added to propagate the culture. The proportion of productively infected CD4 ϩ T cells was calculated with the formula for Poisson distribution, , in which F 0 is the fraction of negative cultures. F = Ϫln(F ) 0 PBMC from wells tested positive were transferred to 25-mL culture flasks containing fresh PHA-stimulated PBL in 5 mL 6 5 ϫ 10 of medium to grow virus stocks. From these cultures, the cell-free supernatant was stored at Ϫ70ЊC until use. To the remaining PBMC, MT2 cells ( ) were added to analyze the syncytium- 6 1 ϫ 10 inducing capacity of the virus clones [34] . The titer of the virus stocks was quantified by determination of the TCID 50 in PHAstimulated PBL derived from a healthy blood donor with the common CCR5 genotype.
Cell lines. Human astroglioma U87 cell lines stably expressing CD4 and coexpressing CCR1, CCR2b, CCR3, CCR5, or CXCR4 were grown in Iscove's medium supplemented with 10% fetal calf serum, 5 mg/mL Polybrene, 100 U/mL penicillin, 100 mg/mL streptomycin, and 1 mg/mL puromycine. The U87 CD4 control cell line was grown in the same medium without puromycine.
CCR3, CCR5, and CXCR4 expression on the corresponding U87 cell lines was monitored by flow cytometry. Staining for CCR3 and CCR5 (2D7; Becton Dickinson, Mountain View, CA) was performed by use of unlabeled monoclonal antibodies, followed by fluorescein isothiocyanate-conjugated goat anti-mouse IgG (CLB, Amsterdam, The Netherlands), blocking with normal mouse sera and staining with phosphatidylethanolamine (PE)-conjugated anti-CD4 monoclonal antibody (CLB). CCR3 monoclonal antibody (7B11) was obtained from Leukosite (Cambridge, MA), through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH [35, 36] . For staining of the U87-CXCR4 cell line, PE-conjugated anti-CXCR4 monoclonal antibody (12G5; Becton Dickinson) and Tri Color-conjugated anti-CD4 (CALTAG Laboratories, South San Francisco) were used. Markers were set by use of isotype matched control antibodies. Primers for HPRT [37] were used as a positive control for RNA preparations. PCR was done on RNA, without a prior RT reaction, to check for contamination of the RNA preparations with chromosomal DNA. PCR products were analyzed on an ethidium bromide-stained 0.8% agarose gel.
Analysis of HIV coreceptor usage. From each individual, 2-9 biological virus clones per time point were analyzed for their coreceptor use, with, on average, 5 virus clones from early and 6 clones from late time points. Selection of virus clones was such that clones with different time points of first detection during clonal isolation were included. To be able to study a sufficient number of clones from progressor ACH 172, who also had a low cellular infectious load at later time points, biological HIV-1 clones obtained from 2 late time points were used for analysis. In addition, HIV-1 biological clones from multiple time points from progressors ACH 617 and ACH 638 were analyzed: this allowed a more detailed analysis of the association between viral load and coreceptor use.
Two primary SI HIV-1 clones, ACH 39.28.H5 and ACH 208.13.B1, with a known ability to use CCR3 and CXCR4 or CCR5 and CXCR4, respectively, and the HIV-1 variant IIIB, a kind gift of Dr. R. Gallo, were used as controls. For all 3 control viruses, an inoculum of 10 2 TCID 50 /mL was shown to be sufficient to establish infection in the U87 cell lines expressing the appropriate coreceptors.
To determine coreceptor use of biological virus clones, 10 4 cells of each U87 cell line were seeded in 96-well plates, and after 24 h these were inoculated with 0.2 mL of the different HIV-1 clones. The range of the inoculum size of the different virus clones obtained [33] .
Results
LTSs in general have a low viral load consisting of only NSI HIV-1 variants. However, 50% of AIDS patients also carry only NSI HIV-1 variants, but these generally have a high viral load. Here we studied whether differences in the evolution of coreceptor usage between NSI variants from LTSs and progressors could account for the differences in changes in the in vivo viral load and in the clinical course of HIV-1 infection. Biological virus clones were isolated from PBMC obtained early and late in infection from 2 LTSs (ACH 441 and 583) who continuously had a low viral load, and from 1 LTS (ACH 68), 2 rapid progressors (ACH 53, 424), and 1 typical progressor (ACH 142) with increasing viral load (figure 1). At the late time point of virus isolation, the progressors had a high viral load. All individuals had the common CCR5 and CCR2b genotype. Coreceptor use was studied by inoculation of the U87 cell lines expressing CD4 alone or coexpressing CD4 and CCR1, CCR2b, CCR3, CCR5, or CXCR4. Expression of the coreceptors was monitored by flow cytometry analyses for CCR3, CCR5 and CXCR4 (figure 2A) and by RT-PCR for CCR1 and CCR2 (figure 2B). Moreover, functioning of CCR3, CCR5, and CXCR4 was shown by the use of control viruses with a known coreceptor usage (table 1) .
All NSI HIV-1 clones were able to productively infect the CD4 and CCR5 coexpressing U87 cell line (table 2) . However, irrespective of the moment of isolation or the clinical course of the patient from whom the clones were isolated, none of the NSI HIV-1 clones was able to replicate in the U87 cell lines expressing CD4 and one of the other coreceptors.
It could be envisaged that besides the currently known receptors expressed on the U87 cell lines, other chemokine receptors expressed on PBMC could function as additional coreceptors for these NSI HIV-1 clones. To study this possibility and to exclude an in vitro effect exerted by the use of U87 cell lines, PHA-stimulated PBL obtained from a healthy blood donor with a CCR5 D32 homozygous genotype were infected with the biological HIV-1 clones under study. In parallel, PHA-stimulated PBL, derived from a CCR5 wild-type donor, were inoculated. Flow cytometry analysis revealed the expression of CD4 and CXCR4 on cells derived from both donors, but CCR5 expression was only detected on cells of the donor with the common CCR5 genotype (data not shown). Also, the presence of mRNA for CCR1, CCR2b, CCR3, CCR4, CCR5, and CXCR4 was confirmed on cells of both donors by RT-PCR (data not shown). In agreement with our observations of the U87 cell lines, none of the NSI virus clones was able to establish infection of the homozygous CCR5 D32 cells. This observation excluded the capacity to use coreceptors that are expressed on CD4 ϩ T cells other than the ones tested on the U87 cell lines. The 3 control viruses with the SI phenotype did establish a productive infection in the PBL derived from the CCR5 D32 homozygous blood donor, as well as in PBL derived from the blood donor with the common CCR5 genotype (table 1) .
CCR5 D32 and CCR2b-64I have both been associated with a delayed HIV-1 disease progression [24] [25] [26] [27] [28] [29] . However, among individuals with a rapid clinical course, CCR5 D32 heterozygotes and CCR2b-64I carriers have been identified. It has been argued that disease progression in these individuals is mediated by SI HIV-1 variants that can bypass CCR5 genetic defects. In our cohort, however, some CCR5 D32 heterozygotes and individuals with the CCR2b-64I mutation showed a rapid disease progression in the presence of only NSI HIV-1 variants. Therefore, we analyzed the coreceptor use of NSI variants isolated early and late in the course of infection from 3 LTSs with a CCR5 D32 heterozygous genotype (ACH 16, 78, 434), 1 LTS with a CCR2b-64I heterozygous genotype (ACH 750), and 1 LTS with a CCR5 D32/CCR2b-64I heterozygous genotype (ACH 337). This was compared with the coreceptor repertoire of NSI HIV-1 variants isolated from 2 rapid progressors (ACH 172, 638), a typical progressor (ACH 38), and a slow progressor (ACH 617) with a CCR5 D32 heterozygous genotype and from a typical progressor (ACH 19) heterozygous for CCR2b 64I. The late time point of virus isolation coincided with an increased viral load in the progressors and also to some extent in LTSs ACH 337 and ACH 750 ( figure 1, table 3 ). All NSI HIV-1 biological clones, irrespective of the time point of isolation in the clinical course of infection, were restricted to the use of CCR5. None of these NSI HIV-1 clones were able to replicate in cells expressing CD4 in combination with CCR1, CCR2b, CCR3, or CXCR4 (table 3) . In agreement with these observations, none of the virus clones was able to productively infect the PBMC from the CCR5 D32 heterozygous blood donor.
Discussion
Recently, several groups have described a correlation between changes in viral coreceptor use and disease progression in HIV-1 infected individuals [4, 5, 22, 23] . In these studies, HIV-1 coreceptor use evolution was found to be associated with conversion of the NSI to the SI HIV-1 phenotype. However, ∼50% of HIV-1 infected individuals progress to AIDS in the absence of SI HIV-1 variants [20, 38] . The NSI variants isolated from all these individuals in general show increased replication kinetics compared with NSI HIV-1 isolated from LTSs, giving rise to an increased cellular infectious load [18] . Rapid disease progression in the absence of SI HIV-1 variants can even be observed for HIV-1 infected individuals with a CCR5 D32 heterozygous genotype or a CCR2b 64I genotype [24, 25] . These observations prompted us to study whether in those individuals that do not develop SI HIV-1 variants, development of NSI HIV-1 that is able to use multiple coreceptors is associated with disease progression.
Restricted CCR5 use of NSI HIV-1 clones that were isolated early and late in infection from LTSs was observed, which appeared to be in good agreement with the absence of disease progression in these individuals. However, biological NSI HIV-1 clones obtained early and late in infection from individuals with a progressive disease course also could only use CCR5. This excluded evolution of coreceptor use as an important determinant of disease progression of individuals harboring solely NSI HIV-1 variants. Also in individuals with a CCR5 D32 heterozygous genotype, in whom CCR5 functioning is considered to be suboptimal [39] , HIV-1 evolution was not driven toward alternative coreceptor use.
It is feasible that NSI HIV-1 variants associated with a pro- gressive disease course may use other, as yet unidentified, coreceptors. Indeed, CCR8, GPR15, and STRL33, which are expressed on CD4 ϩ T cells, have been described as a fusion cofactor for HIV-1 [40] [41] [42] [43] [44] . However, none of the 178 tested NSI HIV-1 variants isolated from 16 different individuals was able to productively infect PBMCs derived from a healthy blood donor with the CCR5 D32 homozygous mutant genotype or the U87-CD4 cell line. This makes it unlikely that any of the coreceptors expressed on PBMC will play a major role in NSI HIV-1 infection, although a defect in yet-unidentified coreceptors in conjunction with the CCR5 mutations cannot be excluded. Alternatively, NSI HIV-1 variants in individuals with a progressive clinical course may evolve to viruses with a higher affinity for CCR5 and/or CD4. This could contribute to the increased cellular infectious load also associated with NSI HIV-1 disease progression [18] .
Our findings are in accordance with the restricted CCR5 use found by other groups for primary NSI bulk isolates [2, 4, 5, 22] or NSI HIV-1 clones [22] . CCR2b, CCR3, and CXCR4 use has been reported, but only for HIV-1 luciferase reporter viruses pseudotyped with NSI envelopes. However, even these viruses mainly used CCR5 for entry [4, 22] , and their use of CCR2b, CCR3, and CXCR4 coreceptors may be caused by the artificial system.
Although the identification of novel HIV-1 coreceptors continues [44] [45] [46] [47] [48] [49] , in this study we have shown that NSI variants, even those associated with disease progression, seem to be restricted to the use of CCR5. Others have shown that the majority of SI variants are CCR5 and/or CXCR4 restricted [2] [3] [4] 50] . These findings indicate that the number of coreceptors that will have to be targeted in vivo to control HIV-1 infection may still be limited. Therefore, in addition to interfering with RT by use of reverse transcriptase inhibitors and the processing of immature proteins with protease inhibitors, targeting HIV-1 entry remains a promising additional strategy to delay progression to AIDS.
